BCYC Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
629.0K
-29.1%
887.0K
-98.2%
48.0M
+308.7%
11.7M
+301.8%
2.9M
Cost of Revenue
0
0
0
0
0
Gross Profit
629.0K
-29.1%
887.0K
-98.2%
48.0M
+308.7%
11.7M
+301.8%
2.9M
Operating Expenses
55.2M
-16.8%
66.4M
-8.7%
72.7M
-6.0%
77.3M
-13.7%
89.5M
R&D
41.2M
-15.8%
48.9M
-5.5%
51.8M
-11.4%
58.4M
-17.7%
71.0M
SG&A
14.0M
-19.7%
17.5M
-16.4%
20.9M
+10.8%
18.9M
+2.0%
18.5M
Operating Income
-54559000
+16.7%
-65482000
-165.0%
-24708000
+62.3%
-65551000
+24.3%
-86602000
EBITDA
-53492000
+16.9%
-64353000
-175.3%
-23372000
+63.4%
-63795000
+24.9%
-84906000
Net Income
-50333000
+17.2%
-60825000
-201.8%
-20154000
+65.9%
-59100000
+25.1%
-78952000
EPS (Basic)
$-0.72
+17.2%
$-0.87
-200.0%
$-0.29
+65.9%
$-0.85
+25.4%
$-1.14
EPS (Diluted)
$-0.72
+17.2%
$-0.87
-200.0%
$-0.29
+65.9%
$-0.85
+25.4%
$-1.14
Shares (Diluted)
69.8M
+0.2%
69.7M
+0.5%
69.4M
+0.1%
69.3M
+0.1%
69.3M
Bicycle Therapeutics plc American (BCYC) โ€” Financials